Fresenius takes full control of mAbxience in EUR 750 million biopharma deal
Fresenius will buy the last 45% of mAbxience for up to EUR 750 million. The move puts all of mAbxience under Fresenius Kabi, pushing the #FutureFresenius plan forward.
Finance Deal and Regulatory Terms 1 article
Finance Deal and Regulatory Terms is a GenoMethods taxonomy category for the vocabulary used to interpret biotechnology financing, transactions, valuation, intellectual property, market access and drug regulation. It groups concepts such as capital raises, licensing economics, royalties, approval pathways and reimbursement rather than representing a company or technology. The category helps connect scientific development with the financial and regulatory structures that determine how biotechnology assets are funded, partnered, approved and commercialized.